AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22460947
Drug: Intensive consolidation
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive consolidation therapy (high-dose cytarabine combined with amsacrine or daunorubicin)
Trial: 22460947
Drug: Standard consolidation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard consolidation and maintenance therapy (standard dose cytarabine and daunorubicin)
Trial: 22460947
Drug: Intensive consolidation
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive consolidation therapy
Trial: 22460947
Drug: Standard consolidation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard consolidation and maintenance therapy
Trial: 9498258
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin 2 x 100 U/kg/d s.c. for 4 weeks (n = 90)
Trial: 9498258
Drug: Ticlopidine 2
RxNorm normalized name: ticlopidine 250 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine 2 x 250 mg/d and low molecular weight heparin 2 x 100 U/kg/d s.c. for 4 weeks (n = 72)
Trial: 9498258
Drug: Ticlopidine 2
RxNorm normalized name: ticlopidine 250 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine 2 x 250 mg/d for 4 weeks (n = 125)
Trial: 9498258
Drug: Anticoagulant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulant therapy (phenprocoumon and low molecular weight heparin)
Trial: 9498258
Drug: Phenprocoumon and
RxNorm normalized name: phenprocoumon
DrugBank: Phenprocoumon (DB00946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenprocoumon and low molecular weight heparin
Trial: 2695866
Drug: Low-dose oral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oral contraceptive containing cyproterone acetate
Trial: 2695866
Drug: Other low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Other low-dose oral contraceptives (desogestrel, gestodene)
Trial: 340141
Drug: Pentazocine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentazocine (15 mg) plus Paracetamol (500 mg)
Trial: 340141
Drug: Dextropropoxyphene hydrochloride
RxNorm normalized name: Dextropropoxyphene hydrochloride
DrugBank: Dextropropoxyphene (DB00647)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dextropropoxyphene hydrochloride (32.5 mg) plus Paracetamol (325 mg)
Trial: 21488750
Drug: OROS methylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OROS methylphenidate (MPH) 18-54 mg/day
Trial: 17689968
Drug: Vancomycin (VAN)
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin (VAN) 15 mg/kg
Trial: 17689968
Drug: Teicoplanin (TEC)
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin (TEC) 8 mg/kg
Trial: 10643541
Drug: EPOCH regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPOCH regimen (etoposide 50 mg/m2, vincristine 0.4 mg/m2, doxorubicin 10 mg/m2 continuous infusion days 1-4; cyclophosphamide 750 mg/m2 i.v. bolus day 6; prednisone 60 mg/m2 days 1-6)
Trial: 7605854
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg p.o. daily
Trial: 7605854
Drug: Lansoprazole 60
RxNorm normalized name: dexlansoprazole 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 60 mg p.o. daily
Trial: 7605854
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg p.o. b.d.
Trial: 23478059
Drug: Abagovomab 2
RxNorm normalized name: Abagovomab
DrugBank: Abagovomab (DB16077)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abagovomab 2 mg administered as 1‐mL suspension once every 2 weeks for 6 weeks (induction phase) and then once every 4 weeks (maintenance phase) until recurrence or up to 21 months after random assignment of the last patient.
Trial: 23478059
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered as 1‐mL suspension once every 2 weeks for 6 weeks (induction phase) and then once every 4 weeks (maintenance phase) until recurrence or up to 21 months after random assignment of the last patient.
Trial: 16458970
Drug: Sub-Tenon's capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sub-Tenon's capsule injection of 20 mg triamcinolone acetonide (TA)
Trial: 16458970
Drug: Control eye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control eye (no TA injection)
Trial: 11966483
Drug: Oxytocin infusion
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin infusion (starting at 1 mIU/min, increasing every 30 minutes up to 30 mIU/min)
Trial: 9809179
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of both concentric and eccentric training
Trial: 2676911
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of 18,000 IE retinol, 70 mg L‐cystine, and 7000 mg gelatin
Trial: 365487
Drug: Amikacin (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amikacin (375 mg/d three times i.m.)
Trial: 365487
Drug: Gentamicin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin (80 mg/d three times i.m.)
Trial: 30114561
Drug: Tinzaparin (4500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinzaparin (4500 IU daily until 37 gestational weeks)
Trial: 25197922
Drug: Nebulized 9-mg
RxNorm normalized name: sodium chloride 9 MG/ML [Hydra-Neb]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized 9-mg sodium hyaluronate nasal washes plus saline solution
Trial: 25197922
Drug: Saline alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline alone (5 mL)
Trial: 17396441
Drug: 5 MU/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 MU/m2 IFN-alpha therapy for 6 months
Trial: 17396441
Drug: 10 MU/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 MU/m2 IFN-alpha therapy for 6 months
Trial: 15618257
Drug: Medical abortion
RxNorm normalized name: ABSORPTION BASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical abortion (600 mg mifepristone followed by 1 mg gemeprost)
Trial: 11860971
Drug: Prophylactic laser
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic laser therapy (16 eyes)
Trial: 11860971
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (19 eyes)
Trial: 6112842
Drug: Active antiparkinson
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active antiparkinson (AP) medication
Trial: 30716938
Drug: Information treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Information treatment on biodegradable mulches
Trial: 28944357
Drug: Implant-supported crown
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant-supported crown
Trial: 26755507
Drug: Volasertib 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volasertib 300 mg by intravenous infusion every 3 weeks
Trial: 26755507
Drug: Chemotherapy (investigator's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (investigator's choice of single-agent, nonplatinum, cytotoxic chemotherapy)
Trial: 15751665
Drug: Heparin during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin during CPB in patients with postoperative SIRS (Group B)
Trial: 9858352
Drug: Benzathine penicillin
RxNorm normalized name: Benzathine penicillin G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzathine penicillin plus amoxicillin 2 g and probenecid 500 mg orally three times daily for 10 days
Trial: 1454956
Drug: Experimental Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental Group (exposed to a distinctive stimulus before each infusion of chemotherapy)
Trial: 6230999
Drug: Topical 1.5%
RxNorm normalized name: phenol topical 1.5% topical liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 1.5% erythromycin solution
Trial: 6230999
Drug: Topical 1%
RxNorm normalized name: fluoride topical 1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 1% clindamycin phosphate solution
Trial: 26715213
Drug: CYP2B6 983TC/CC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP2B6 983TC/CC genotype
Trial: 26715213
Drug: C12 between
RxNorm normalized name: C12:0
DrugBank: Lauric acid (DB03017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C12 between 0.47 and 0.76 mg/L
Trial: 23609378
Drug: Typical antipsychotics
RxNorm normalized name: benzocaine Mucous Membrane Topical Solution [Topicale]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Typical antipsychotics (TAs)
Trial: 23609378
Drug: Nonclozapine atypical
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonclozapine atypical antipsychotics (AAs)
Trial: 18235202
Drug: Ganciclovir 50
RxNorm normalized name: ganciclovir 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganciclovir 50 mg/ml
Trial: 17000819
Drug: Standard intraoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intraoperative and postoperative analgesic regimen (morphine sulfate, diclofenac, dextropropoxyphene hydrochloride + acetaminophen prn)
Trial: 17000819
Drug: Continuous paravertebral
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous paravertebral block (for 48 h) and acetaminophen and parecoxib (followed by celecoxib up to 5 days)
Trial: 14582587
Drug: Brief information
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief information + relaxation therapy (BI + RT)
Trial: 27340112
Drug: Escitalopram +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram + internet-delivered cognitive-behavioural therapy (ICBT)
Trial: 20595543
Drug: β1‐adrenoreceptor blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β1‐adrenoreceptor blocker (atenolol; βB) 0.2 mg/kg
Trial: 18032083
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous insulin infusion (CSII) with insulin lispro
Trial: 12402765
Drug: Avelox (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avelox (400 mg/day for 10 days)
Trial: 12402765
Drug: Ofloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (200 mg twice a day for 10 days)
Trial: 2980291
Drug: CR-capsules (controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CR-capsules (controlled release)
Trial: 2980291
Drug: Unixan tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unixan tablets
Trial: 25982544
Drug: simvastatin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: simvastatin (80 mg) once daily
Trial: 21095483
Drug: placebo once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo once daily
Trial: 21515905
Drug: Mental rehearsal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mental rehearsal of upper limb movements during 45-min supervised sessions three times a week and structured independent sessions twice a week
Trial: 19368503
Drug: Selenium supplements
RxNorm normalized name: Selenium supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium supplements (200 microg of selenomethionine)
Trial: 16886974
Drug: Tiagabine (TGB)
DrugBank: Tiagabine (DB00906)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tiagabine (TGB) 20-30 mg/day
Trial: 16886974
Drug: Carbamazepine (CBZ)
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbamazepine (CBZ) 400-800 mg/day
Trial: 16886974
Drug: No-drug group
RxNorm normalized name: Heparin group antithrombotic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-drug group (untreated patients)
Trial: 17307536
Drug: Early inhaled
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early inhaled nitric oxide (iNO) therapy
Trial: 11317659
Drug: Intensive blood-glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive blood-glucose control with metformin (n = 342)
Trial: 11317659
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy primarily with diet (n = 411)
Trial: 8107555
Drug: Acetaminophen administered
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen administered intragastrically in a single dose of 1.0 g.
Trial: 31926063
Drug: BioBase mobile
RxNorm normalized name: Bioease Pain Relieving Cold Therapy
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BioBase mobile app and paired wearable device (BioBeam) used daily for 4 weeks
Trial: 23817682
Drug: Low-dose CT-guided
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose CT-guided biopsy (group B: 120 kv; 10 mA; thickness, 2.0 mm; pitch, 23 mm/rot)
Trial: 22045831
Drug: N-acetylcysteine (NAC;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC; 50 mg/kg by 4 hours followed by 100 mg/kg/d for 48 hours diluted in 5% glucose) and deferoxamine (DFX; at a single dose of 1000 mg diluted in 5% glucose)
Trial: 19745592
Drug: Bendamustine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendamustine (200 mg flat dose on days 1 + 2, repeated at day 28 or upon recovery of neutrophils)
Trial: 3416618
Drug: Orally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered melatonin
Trial: 30717691
Drug: Lower range
RxNorm normalized name: Orange
DrugBank: Orange (DB10549)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower range group (LRG) 0.8‐1.4 mmol/L or 2.5‐4.3 mg/dL
Trial: 30717691
Drug: Higher range
RxNorm normalized name: Orange
DrugBank: Orange (DB10549)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher range group (HRG) 1.8‐2.4 mmol/L or 5.6‐7.4 mg/dL
Trial: 21975926
Drug: Platycodi radix
RxNorm normalized name: Valerianae radix
DrugBank: Platycodon grandiflorus root (DB14347)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platycodi radix extract standardized to 414 mg of platycodin D
Trial: 12661753
Drug: Valacyclovir 500
RxNorm normalized name: valacyclovir 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valacyclovir 500 mg once daily for 16 weeks
Trial: 3928508
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg Voltaren (diclofenac-sodium) before surgery and then 50 mg 3 times a day for 5 days
Trial: 3928508
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination tablets (acetylsalicylic acid 500 mg, caffeine 50 mg, aprobarbital 20 mg, codeine phosphate 10 mg) in the highest recommended dose, 2 tablets when needed at most 3 times a day
Trial: 26639943
Drug: Luseogliflozin 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luseogliflozin 2.5 mg once daily with normal-carbohydrate diet (NCD)
Trial: 26639943
Drug: Luseogliflozin 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luseogliflozin 2.5 mg once daily with low-carbohydrate diet (LCD)
Trial: 24581393
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy followed by external beam radiotherapy (EBRT) with concomitant cisplatin (Arm A)
Trial: 24581393
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy followed by EBRT with concomitant cisplatin plus brachytherapy boost (Arm B)
Trial: 24581393
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy followed by EBRT with concomitant cisplatin (Arm A)
Trial: 22933542
Drug: Vitamin D(3),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D(3), 50,000 IU monthly (n = 102)
Trial: 11576201
Drug: Valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproic acid (300 to 1200 mg per day)
Trial: 11576201
Drug: Valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproic acid (serum levels >50 microg/mL)
Trial: 9819872
Drug: Transdermal glyceryl
RxNorm normalized name: glyceryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal glyceryl trinitrate 5 mg-patches
Trial: 7657848
Drug: Enalapril (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (2.5 mg twice daily)
Trial: 28244635
Drug: linagliptin 5
RxNorm normalized name: linagliptin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: linagliptin 5 mg once daily for 26 weeks
Trial: 26135706
Drug: Oral methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral methylprednisolone 1000 mg once a day for 3 days
Trial: 26135706
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone 1000 mg once a day for 3 days
Trial: 23880625
Drug: B lactis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B lactis + GOS/FOS (10 colony-forming units/g + 0.4 g/100 mL)
Trial: 23880625
Drug: B lactis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B lactis (10⁷ colony-forming units/g)
Trial: 15956071
Drug: Iron-gluconate 62.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron-gluconate 62.5 mg
Trial: 15956071
Drug: Iron-gluconate 125
RxNorm normalized name: Iron(2+) gluconate (1:2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron-gluconate 125 mg
Trial: 15956071
Drug: Control (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0 mg iron-gluconate)
Trial: 15956071
Drug: Iron-gluconate (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron-gluconate (both doses)
Trial: 7576328
Drug: Improved STD
RxNorm normalized name: Improvest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Improved STD treatment services
Trial: 7576328
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard STD treatment)
Trial: 2206015
Drug: GM1 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GM1 treatment
Trial: 6989464
Drug: Therapy with
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy with platelet antiaggregants
Trial: 31431370
Drug: Hyperthermia (HT)
RxNorm normalized name: 5-HT
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperthermia (HT) combined with radiation treatment (RT)
Trial: 31669450
Drug: Modified directly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified directly observed therapy (mDOT)
Trial: 21324181
Drug: Sequential behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential behaviour tailoring condition
Trial: 15581383
Drug: Zolmitriptan 5
RxNorm normalized name: zolmitriptan 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolmitriptan 5 mg ODT
Trial: 11307043
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg L‐Dopa
Trial: 2728828
Drug: 0.03 mg
RxNorm normalized name: biotin 0.03 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03 mg buprenorphine
Trial: 2728828
Drug: 0.045 mg
RxNorm normalized name: biotin 0.045 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.045 mg buprenorphine
Trial: 10858715
Drug: 4% PRO
RxNorm normalized name: Stanimax 2.84% Pro Perio Mouthwash Dental Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% PRO 2000 gel
Trial: 10858715
Drug: 0.5% PRO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% PRO 2000 gel
Trial: 12614254
Drug: Testim 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testim 100 mg/day
Trial: 12614254
Drug: Testim 50
RxNorm normalized name: Testim 50 MG per 5 GM Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testim 50 mg/day
Trial: 10568572
Drug: Campath‐1H monoclonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Campath‐1H monoclonal antibody treatment (5-day pulse)
Trial: 9005794
Drug: Ofloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (200 mg intravenously twice a day for 4 to 6 days, then orally for 4 to 6 days)
Trial: 9005794
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (broad spectrum antibiotics such as amplox, gentamicin, and 3rd generation cephalosporins)
Trial: 30745118
Drug: Radiotherapy combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy combined with long-term androgen deprivation therapy